Literature DB >> 22397921

Differential age- and disease-related effects on the expression of genes related to the arachidonic acid signaling pathway in schizophrenia.

Bin Tang1, Cristina Capitao, Brian Dean, Elizabeth A Thomas.   

Abstract

We have previously identified differential effects of age on global brain gene expression profiles in subjects with schizophrenia compared to normal controls. Here, we have focused on age-related effects of genes associated with the arachidonic acid-related inflammation pathway. Linear correlation analysis of published microarray expression data reveal strong age- and cell-type- specific-effects on the expression of genes related to the arachidonic acid signaling pathway, which differed in control subjects compared to those with schizophrenia. Using real-time qPCR analysis, we validated age and disease effects of arachidonic acid-related genes in a large cohort of subjects with schizophrenia and matched controls (n=76 subjects in total). We found that levels of prostaglandin-endoperoxide synthase 1 (PTGS1; aka COX-1) and prostaglandin-endoperoxide receptor 3 (PTGER3) mRNA are increased, and levels of prostaglandin-endoperoxide synthase 2 (PTGS2; aka COX-2) mRNA are decreased, in older subjects with schizophrenia (> 40years of age) compared to matched normal controls or younger subjects with schizophrenia (< 40years of age). These findings contribute to the accumulating evidence suggesting that inflammatory processes in the CNS contribute to pathophysiology of schizophrenia and further suggest that age may be an important factor in the potential use of anti-inflammatory therapies.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22397921      PMCID: PMC3361581          DOI: 10.1016/j.psychres.2011.09.026

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  38 in total

1.  Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients.

Authors:  J K Yao; S Leonard; R D Reddy
Journal:  Schizophr Res       Date:  2000-03-16       Impact factor: 4.939

2.  COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps.

Authors:  Yuki Nakanishi; Masato Nakatsuji; Hiroshi Seno; Shoko Ishizu; Reiko Akitake-Kawano; Keitaro Kanda; Taro Ueo; Hideyuki Komekado; Mayumi Kawada; Manabu Minami; Tsutomu Chiba
Journal:  Carcinogenesis       Date:  2011-07-05       Impact factor: 4.944

3.  Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics.

Authors:  K Radewicz; L J Garey; S M Gentleman; R Reynolds
Journal:  J Neuropathol Exp Neurol       Date:  2000-02       Impact factor: 3.685

Review 4.  Cyclooxygenases in the central nervous system: implications for treatment of neurological disorders.

Authors:  A Yermakova; M K O'Banion
Journal:  Curr Pharm Des       Date:  2000-11       Impact factor: 3.116

5.  Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia.

Authors:  Norbert Müller; Michael Riedel; Constanze Scheppach; Bernd Brandstätter; Safet Sokullu; Karin Krampe; Markus Ulmschneider; Rolf R Engel; Hans-Jürgen Möller; Markus J Schwarz
Journal:  Am J Psychiatry       Date:  2002-06       Impact factor: 18.112

6.  Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis.

Authors:  M Stolina; S Sharma; Y Lin; M Dohadwala; B Gardner; J Luo; L Zhu; M Kronenberg; P W Miller; J Portanova; J C Lee; S M Dubinett
Journal:  J Immunol       Date:  2000-01-01       Impact factor: 5.422

7.  Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy.

Authors:  W F Gattaz; M Köllisch; T Thuren; J A Virtanen; P K Kinnunen
Journal:  Biol Psychiatry       Date:  1987-04       Impact factor: 13.382

8.  Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients.

Authors:  Meena Arvindakshan; Sandhya Sitasawad; Vijay Debsikdar; Madhav Ghate; Denise Evans; David F Horrobin; Crispin Bennett; Prabhakar K Ranjekar; Sahebarao P Mahadik
Journal:  Biol Psychiatry       Date:  2003-01-01       Impact factor: 13.382

9.  COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy.

Authors:  Norbert Müller; Markus Ulmschneider; Constanze Scheppach; Markus J Schwarz; Manfred Ackenheil; Hans-Jürgen Möller; Rudolf Gruber; Michael Riedel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-02       Impact factor: 5.270

Review 10.  From membrane phospholipid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia?

Authors:  P D Skosnik; J K Yao
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2003-12       Impact factor: 4.006

View more
  17 in total

Review 1.  Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials.

Authors:  Masahiro Nitta; Taishiro Kishimoto; Norbert Müller; Mark Weiser; Michael Davidson; John M Kane; Christoph U Correll
Journal:  Schizophr Bull       Date:  2013-05-29       Impact factor: 9.306

Review 2.  Inflammation and the two-hit hypothesis of schizophrenia.

Authors:  Keith A Feigenson; Alex W Kusnecov; Steven M Silverstein
Journal:  Neurosci Biobehav Rev       Date:  2013-11-15       Impact factor: 8.989

Review 3.  Systemic Biomarkers of Accelerated Aging in Schizophrenia: A Critical Review and Future Directions.

Authors:  Tanya T Nguyen; Lisa T Eyler; Dilip V Jeste
Journal:  Schizophr Bull       Date:  2018-02-15       Impact factor: 9.306

4.  Manganese-enhanced magnetic resonance imaging reveals increased DOI-induced brain activity in a mouse model of schizophrenia.

Authors:  Natalia V Malkova; Joseph J Gallagher; Collin Z Yu; Russell E Jacobs; Paul H Patterson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-02       Impact factor: 11.205

5.  Blood chromatin as a biosensor of the epigenetic milieu: a tool for studies in living psychiatric patients.

Authors:  Rajiv P Sharma
Journal:  Epigenomics       Date:  2012-10       Impact factor: 4.778

6.  Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis.

Authors:  Gursharan Chana; Chad A Bousman; Tammie T Money; Andrew Gibbons; Piers Gillett; Brian Dean; Ian P Everall
Journal:  Front Cell Neurosci       Date:  2013-06-26       Impact factor: 5.505

7.  Meta gene set enrichment analyses link miR-137-regulated pathways with schizophrenia risk.

Authors:  Carrie Wright; Vince D Calhoun; Stefan Ehrlich; Lei Wang; Jessica A Turner; Nora I Perrone- Bizzozero
Journal:  Front Genet       Date:  2015-04-20       Impact factor: 4.599

8.  Age and haplotype variations within FADS1 interact and associate with alterations in fatty acid composition in human male cortical brain tissue.

Authors:  Erika Freemantle; Aleksandra Lalovic; Naguib Mechawar; Gustavo Turecki
Journal:  PLoS One       Date:  2012-08-10       Impact factor: 3.240

9.  Polymorphisms in MIR137HG and microRNA-137-regulated genes influence gray matter structure in schizophrenia.

Authors:  C Wright; C N Gupta; J Chen; V Patel; V D Calhoun; S Ehrlich; L Wang; J R Bustillo; N I Perrone-Bizzozero; J A Turner
Journal:  Transl Psychiatry       Date:  2016-02-02       Impact factor: 6.222

Review 10.  Linking Activation of Microglia and Peripheral Monocytic Cells to the Pathophysiology of Psychiatric Disorders.

Authors:  Yuta Takahashi; Zhiqian Yu; Mai Sakai; Hiroaki Tomita
Journal:  Front Cell Neurosci       Date:  2016-06-03       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.